New lupus drug shows promise in Mid-Stage trial
NCT ID NCT05796206
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new medicine called MIL62 in 120 adults with lupus, a chronic autoimmune disease. The goal is to see if MIL62 can reduce disease activity better than a placebo. Participants must have active lupus and be on a stable treatment plan. The study is not a cure but aims to better control the disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC LUPUS ERYTHEMATOSUS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Peking University People's Hospital
Beijing, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new biologic tame lupus flares?
- Could a single injection tame lupus and Sjögren's?
- Can a single infusion tame tough lupus?
- Can a single drug calm three different autoimmune diseases? a new trial puts ATG-201 to the test.
- Can genetics and environment explain lupus in the gullah population?
- Can a smartphone app bridge the lupus care gap for women of color?